DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Hepatitis Drug Market & Clinical Trials Insight 2023" report to their offering.
The global hepatitis drug market is expected to surpass USD 70 Billion by 2023 with the rising number of infected population, growing consumption of alcohol and drugs and the improvement in the access to hepatitis medicines. The introduction of generic drugs of hepatitis has also changed the market dynamics across the globe. With the increase of people being able to afford the generic versions, the usage rates of drugs are expected to grow rapidly over the next few years.
The past two decades have witnessed substantial progress in the treatment of hepatitis virus infection and it includes the introduction of nucleotides and nucleoside analogues, interferons, toll like receptors and protease inhibitors which revolutionized the hepatitis disease management.
With the recent dramatic progress in development of potent antiviral drugs for chronic hepatitis virus infection, virological responses are achievable in almost all patients. Most clinical practice guidelines strongly recommended the treatment of patients with antiviral agents if they have proper indications. The main aim of antiviral treatment is to inhibit the hepatitis virus replication and improve the liver pathology but it rarely cures chronic hepatitis infection.
- Arbutus Biopharma
- Benitec Biopharma
- Biostar Pharmaceuticals
- Bristol-Myers Squibb
- Gilead Sciences
- Janssen Pharmaceuticals
- Novira Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/jnjns6/global_hepatitis